SUPERNUS PHARMACEUTICALS, INC. reported results for the 2026 quarter with revenue of $219.06M, up from $165.45M a year earlier, while the company posted a net loss of ($58.37M) and diluted loss per share of ($1.01) versus prior-year net income of $22.5M and EPS of $0.4.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$219.06M$165.45M32.4% | Net income²($58.37M)$22.5M(359.4%) | Diluted EPS³($1.01)$0.4(352.5%) |
¹ Reported as “Total revenues”. ² Reported as “Net earnings (loss)”. ³ Reported as “Earnings (loss) per share”.
Business Highlights
- Revenue growth of 35% year-to-date was driven by Qelbree, the ONAPGO launch and contributions from the ZURZUVAE collaboration following the Sage acquisition.
- Qelbree prescriptions increased 17% quarter-over-quarter, and ONAPGO has been ramping since April 2025 with resumption of new patient starts.
- Growth from newer launches offset declines in legacy products facing generic erosion.
- Pipeline and operations: ongoing Phase 2b studies for SPN-817 and SPN-820, and the company is pursuing a second supplier for ONAPGO.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.